Logo image of TMDX

TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis

NASDAQ:TMDX - Nasdaq - US89377M1099 - Common Stock - Currency: USD

116.88  +4.42 (+3.93%)

After market: 116.88 0 (0%)

Fundamental Rating

5

TMDX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 187 industry peers in the Health Care Equipment & Supplies industry. TMDX has an average financial health and profitability rating. TMDX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year TMDX was profitable.
TMDX had a positive operating cash flow in the past year.
TMDX had negative earnings in 4 of the past 5 years.
In the past 5 years TMDX reported 4 times negative operating cash flow.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

The Return On Assets of TMDX (5.84%) is better than 86.10% of its industry peers.
TMDX has a Return On Equity of 18.38%. This is amongst the best in the industry. TMDX outperforms 92.51% of its industry peers.
Looking at the Return On Invested Capital, with a value of 5.31%, TMDX is in the better half of the industry, outperforming 79.14% of the companies in the same industry.
Industry RankSector Rank
ROA 5.84%
ROE 18.38%
ROIC 5.31%
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

TMDX has a Profit Margin of 10.03%. This is amongst the best in the industry. TMDX outperforms 83.96% of its industry peers.
With a decent Operating Margin value of 10.76%, TMDX is doing good in the industry, outperforming 78.07% of the companies in the same industry.
Looking at the Gross Margin, with a value of 59.47%, TMDX is in line with its industry, outperforming 58.82% of the companies in the same industry.
TMDX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.76%
PM (TTM) 10.03%
GM 59.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), TMDX is destroying value.
TMDX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TMDX has more shares outstanding
Compared to 1 year ago, TMDX has an improved debt to assets ratio.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

TMDX has an Altman-Z score of 4.69. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
TMDX has a Altman-Z score of 4.69. This is in the better half of the industry: TMDX outperforms 75.94% of its industry peers.
TMDX has a Debt/Equity ratio of 1.92. This is a high value indicating a heavy dependency on external financing.
TMDX has a worse Debt to Equity ratio (1.92) than 85.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.92
Debt/FCF N/A
Altman-Z 4.69
ROIC/WACC0.65
WACC8.21%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

TMDX has a Current Ratio of 9.10. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of TMDX (9.10) is better than 91.98% of its industry peers.
A Quick Ratio of 8.32 indicates that TMDX has no problem at all paying its short term obligations.
TMDX has a Quick ratio of 8.32. This is amongst the best in the industry. TMDX outperforms 91.98% of its industry peers.
Industry RankSector Rank
Current Ratio 9.1
Quick Ratio 8.32
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 500.00%, which is quite impressive.
TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 64.43%.
Measured over the past years, TMDX shows a very strong growth in Revenue. The Revenue has been growing by 79.64% on average per year.
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)64.43%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%48.21%

3.2 Future

Based on estimates for the next years, TMDX will show a very strong growth in Earnings Per Share. The EPS will grow by 49.75% on average per year.
The Revenue is expected to grow by 21.08% on average over the next years. This is a very strong growth
EPS Next Y82.44%
EPS Next 2Y59.67%
EPS Next 3Y47.23%
EPS Next 5Y49.75%
Revenue Next Year34.91%
Revenue Next 2Y27.64%
Revenue Next 3Y24.32%
Revenue Next 5Y21.08%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 -4 -6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 85.94 indicates a quite expensive valuation of TMDX.
Based on the Price/Earnings ratio, TMDX is valued a bit cheaper than 64.17% of the companies in the same industry.
TMDX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.41.
A Price/Forward Earnings ratio of 45.39 indicates a quite expensive valuation of TMDX.
Based on the Price/Forward Earnings ratio, TMDX is valued a bit cheaper than 68.45% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.19, TMDX is valued a bit more expensive.
Industry RankSector Rank
PE 85.94
Fwd PE 45.39
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 65.78% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 54.03
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

TMDX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 47.23% in the coming years.
PEG (NY)1.04
PEG (5Y)N/A
EPS Next 2Y59.67%
EPS Next 3Y47.23%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TMDX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSMEDICS GROUP INC

NASDAQ:TMDX (7/14/2025, 4:16:37 PM)

After market: 116.88 0 (0%)

116.88

+4.42 (+3.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners121.41%
Inst Owner Change0%
Ins Owners2.98%
Ins Owner Change18.64%
Market Cap3.95B
Analysts81.25
Price Target141.78 (21.3%)
Short Float %23.96%
Short Ratio7.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)91.9%
Min EPS beat(2)16.42%
Max EPS beat(2)167.38%
EPS beat(4)3
Avg EPS beat(4)46.83%
Min EPS beat(4)-59.86%
Max EPS beat(4)167.38%
EPS beat(8)6
Avg EPS beat(8)142.41%
EPS beat(12)9
Avg EPS beat(12)105.32%
EPS beat(16)10
Avg EPS beat(16)74.65%
Revenue beat(2)2
Avg Revenue beat(2)10.96%
Min Revenue beat(2)8.12%
Max Revenue beat(2)13.8%
Revenue beat(4)3
Avg Revenue beat(4)6.97%
Min Revenue beat(4)-7.28%
Max Revenue beat(4)13.8%
Revenue beat(8)7
Avg Revenue beat(8)13.88%
Revenue beat(12)11
Avg Revenue beat(12)16.77%
Revenue beat(16)14
Avg Revenue beat(16)17.35%
PT rev (1m)3.73%
PT rev (3m)20.48%
EPS NQ rev (1m)0.12%
EPS NQ rev (3m)23.21%
EPS NY rev (1m)2.53%
EPS NY rev (3m)23.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.37%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)6.98%
Valuation
Industry RankSector Rank
PE 85.94
Fwd PE 45.39
P/S 8.1
P/FCF N/A
P/OCF 80.07
P/B 14.85
P/tB 15.65
EV/EBITDA 54.03
EPS(TTM)1.36
EY1.16%
EPS(NY)2.57
Fwd EY2.2%
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)1.46
OCFY1.25%
SpS14.43
BVpS7.87
TBVpS7.47
PEG (NY)1.04
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.84%
ROE 18.38%
ROCE 6.72%
ROIC 5.31%
ROICexc 8.79%
ROICexgc 9.06%
OM 10.76%
PM (TTM) 10.03%
GM 59.47%
FCFM N/A
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score6
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 1.92
Debt/FCF N/A
Debt/EBITDA 6.88
Cap/Depr 521.51%
Cap/Sales 23.07%
Interest Coverage 250
Cash Conversion 66.63%
Profit Quality N/A
Current Ratio 9.1
Quick Ratio 8.32
Altman-Z 4.69
F-Score6
WACC8.21%
ROIC/WACC0.65
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y82.44%
EPS Next 2Y59.67%
EPS Next 3Y47.23%
EPS Next 5Y49.75%
Revenue 1Y (TTM)64.43%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%48.21%
Revenue Next Year34.91%
Revenue Next 2Y27.64%
Revenue Next 3Y24.32%
Revenue Next 5Y21.08%
EBIT growth 1Y529.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year231.21%
EBIT Next 3Y84.76%
EBIT Next 5Y66.53%
FCF growth 1Y-34.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y236.91%
OCF growth 3YN/A
OCF growth 5YN/A